OBM Geriatrics

(ISSN 2638-1311)

OBM Geriatrics is an Open Access journal published quarterly online by LIDSEN Publishing Inc. The journal takes the premise that innovative approaches – including gene therapy, cell therapy, and epigenetic modulation – will result in clinical interventions that alter the fundamental pathology and the clinical course of age-related human diseases. We will give strong preference to papers that emphasize an alteration (or a potential alteration) in the fundamental disease course of Alzheimer’s disease, vascular aging diseases, osteoarthritis, osteoporosis, skin aging, immune senescence, and other age-related diseases.

Geriatric medicine is now entering a unique point in history, where the focus will no longer be on palliative, ameliorative, or social aspects of care for age-related disease, but will be capable of stopping, preventing, and reversing major disease constellations that have heretofore been entirely resistant to interventions based on “small molecular” pharmacological approaches. With the changing emphasis from genetic to epigenetic understandings of pathology (including telomere biology), with the use of gene delivery systems (including viral delivery systems), and with the use of cell-based therapies (including stem cell therapies), a fatalistic view of age-related disease is no longer a reasonable clinical default nor an appropriate clinical research paradigm.

Precedence will be given to papers describing fundamental interventions, including interventions that affect cell senescence, patterns of gene expression, telomere biology, stem cell biology, and other innovative, 21st century interventions, especially if the focus is on clinical applications, ongoing clinical trials, or animal trials preparatory to phase 1 human clinical trials.

Papers must be clear and concise, but detailed data is strongly encouraged. The journal publishes research articles, reviews, communications and technical notes. There is no restriction on the length of the papers and we encourage scientists to publish their results in as much detail as possible.

Archiving: full-text archived in CLOCKSS.

Rapid publication: manuscripts are undertaken in 12 days from acceptance to publication (median values for papers published in this journal in 2021, 1-2 days of FREE language polishing time is also included in this period). 

Current Issue: 2023  Archive: 2022 2021 2020 2019 2018 2017

Special Issue

Prostate Cancer in Older Men

Submission Deadline: December 30, 2021 (Open) Submit Now

Guest Editor

Chris H. Bangma, MD, PhD

Professor, Chair urology, Erasmus MC, Department of Urology, Rotterdam, Netherlands


Research Interests: Urology; prostate cancer, prostate diseases; cancer therapy; bladder cancer; urologic oncology; prostate

About This Topic

Prostate cancer is one of the most frequent malignant tumor amongst elderly men. Its clinical course can be highly variable. It is a well-known saying that most patients do not die of, but with prostate cancer. Like in any cancer, the constant threat of the presence of a potentially lethal disease can affect the quality of life of patients and partners considerably. Therefore overdiagnosis of likely harmless low risk cancers, and overtreatment of these, are important to consider in our care for the elderly. Prevention is feasible, but at which price?

Meanwhile, the therapeutic options for prostate cancers that are judged relevant to negatively affect the last period of life, are multiple, but not without side effects. The development of new diagnostic technologies has provided options to treat local tumors and regional lymph node metastases better. New modalities for systemic treatment in the metastatic stage are rapidly developing, and targeted treatments based on molecular tumor profiles are emerging. The field of theragnostics with specific radioactive tracers increases the number of treatment choices in case of disseminated disease.

This special issue of OBM Geriatrics brings forward the dilemma for elderly citizens of screening for prostate cancer at an asymptomatic stage with the intention of preventing painful metastatic disease. It will illustrate the impact of the effects of local and systemic disease, and discusses the indications for interventions. The protracted course of prostate cancer offers challenges to patients, physicians, and oncologic nurses that need a balancing act between life expectancy and treatment related side effects. Whether to test early, or to wait and see till palliation is needed in the population at higher age, remains the central problem in the contributions of this special issue.